{"id":"https://openalex.org/W2890318130","doi":"https://doi.org/10.1080/13696998.2018.1521416","title":"Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US","display_name":"Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US","publication_year":2018,"publication_date":"2018-09-07","ids":{"openalex":"https://openalex.org/W2890318130","doi":"https://doi.org/10.1080/13696998.2018.1521416","mag":"2890318130","pmid":"https://pubmed.ncbi.nlm.nih.gov/30188231"},"language":"en","primary_location":{"id":"doi:10.1080/13696998.2018.1521416","doi":"https://doi.org/10.1080/13696998.2018.1521416","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2018.1521416","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1521416?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1521416?needAccess=true&role=button","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112412595","display_name":"Ralph P. Insinga","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ralph P. Insinga","raw_affiliation_strings":["Merck Sharp & Dohme Corp., Center for Observational and Real-World Evidence, North Wales, PA, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Sharp & Dohme Corp., Center for Observational and Real-World Evidence, North Wales, PA, USA;","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021742756","display_name":"David J. Vanness","orcid":"https://orcid.org/0000-0002-9790-2988","observed_orcids":["https://orcid.org/0000-0002-9790-2988"]},"institutions":[{"id":"https://openalex.org/I130769515","display_name":"Pennsylvania State University","ror":"https://ror.org/04p491231","country_code":"US","type":"education","lineage":["https://openalex.org/I130769515"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David J. Vanness","raw_affiliation_strings":["Department of Health Policy and Administration, Pennsylvania State University, State College, PA, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Policy and Administration, Pennsylvania State University, State College, PA, USA;","institution_ids":["https://openalex.org/I130769515"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075372434","display_name":"Josephine Louella Feliciano","orcid":"https://orcid.org/0009-0008-8163-2304","observed_orcids":["https://orcid.org/0009-0008-8163-2304"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Josephine L. Feliciano","raw_affiliation_strings":["The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA;","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103506863","display_name":"Kristel Vandormael","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121359","display_name":"MSD (Belgium)","ror":"https://ror.org/02j4p4h77","country_code":"BE","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210121359"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Kristel Vandormael","raw_affiliation_strings":["Merck Sharp & Dohme, HTA Statistics Europe, Brussels, Belgium;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Sharp & Dohme, HTA Statistics Europe, Brussels, Belgium;","institution_ids":["https://openalex.org/I4210121359"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077377196","display_name":"Sory Traor\u00e9","orcid":"https://orcid.org/0000-0002-1479-2737","observed_orcids":["https://orcid.org/0000-0002-1479-2737"]},"institutions":[{"id":"https://openalex.org/I4210087189","display_name":"MSD (UK) Limited (United Kingdom)","ror":"https://ror.org/004nn4n27","country_code":"GB","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210087189"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Sory Traore","raw_affiliation_strings":["Merck Sharp & Dohme, HTA Statistics Europe, London, UK;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Sharp & Dohme, HTA Statistics Europe, London, UK;","institution_ids":["https://openalex.org/I4210087189"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086954528","display_name":"Thomas A. Burke","orcid":"https://orcid.org/0000-0001-6335-0559","observed_orcids":["https://orcid.org/0000-0001-6335-0559"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Burke","raw_affiliation_strings":["Merck Sharp & Dohme Corp., Center for Observational and Real-World Evidence, Rahway, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck Sharp & Dohme Corp., Center for Observational and Real-World Evidence, Rahway, NJ, USA","institution_ids":["https://openalex.org/I1285764155"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5112412595"],"corresponding_institution_ids":["https://openalex.org/I1285764155"],"apc_list":null,"apc_paid":null,"fwci":18.2166,"has_fulltext":true,"cited_by_count":99,"citation_normalized_percentile":{"value":0.99194955,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"21","issue":"12","first_page":"1191","last_page":"1205"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12708","display_name":"Economic and Financial Impacts of Cancer","score":0.0038999998942017555,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9589999914169312},{"id":"https://openalex.org/keywords/non-squamous-non-small-cell-lung-cancer","display_name":"non-squamous non-small cell lung cancer","score":0.9200000166893005},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.656000018119812},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8820000290870667},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.7200000286102295},{"id":"https://openalex.org/keywords/pemetrexed","display_name":"pemetrexed","score":0.7689999938011169},{"id":"https://openalex.org/keywords/platinum-based-chemotherapy","display_name":"platinum-based chemotherapy","score":0.7239999771118164},{"id":"https://openalex.org/keywords/keynote-189","display_name":"KEYNOTE-189","score":0.8119999766349792},{"id":"https://openalex.org/keywords/seer-database","display_name":"SEER database","score":0.4180000126361847},{"id":"https://openalex.org/keywords/survival-extrapolation","display_name":"survival extrapolation","score":0.6919999718666077},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8809999823570251},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.42800000309944153},{"id":"https://openalex.org/keywords/indirect-treatment-comparison","display_name":"indirect treatment comparison","score":0.5669999718666077},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.7099999785423279}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.9137839674949646},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8849373459815979},{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.8005778193473816},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6289107799530029},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6215870976448059},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.549038827419281},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.5340347290039062},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.49318522214889526},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4866243302822113},{"id":"https://openalex.org/C515549039","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost-effectiveness analysis","level":3,"score":0.4215676486492157},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2931969165802002},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.17253300547599792},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.10802781581878662},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068437","descriptor_name":"Pemetrexed","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D000068437","descriptor_name":"Pemetrexed","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005102","descriptor_name":"Health Expenditures","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017059","descriptor_name":"Models, Econometric","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017671","descriptor_name":"Platinum Compounds","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D017671","descriptor_name":"Platinum Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1080/13696998.2018.1521416","doi":"https://doi.org/10.1080/13696998.2018.1521416","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2018.1521416","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1521416?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},{"id":"pmid:30188231","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30188231","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medical economics","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":{"id":"doi:10.1080/13696998.2018.1521416","doi":"https://doi.org/10.1080/13696998.2018.1521416","is_oa":true,"landing_page_url":"https://doi.org/10.1080/13696998.2018.1521416","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1521416?needAccess=true&role=button","source":{"id":"https://openalex.org/S155267287","display_name":"Journal of Medical Economics","issn_l":"1369-6998","issn":["1369-6998","1941-837X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320449","host_organization_name":"Informa","host_organization_lineage":["https://openalex.org/P4310320449"],"host_organization_lineage_names":["Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medical Economics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332932","display_name":"Merck Sharp and Dohme","ror":"https://ror.org/004nn4n27"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2890318130.pdf","grobid_xml":"https://content.openalex.org/works/W2890318130.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W1548882558","https://openalex.org/W2005947177","https://openalex.org/W2019607817","https://openalex.org/W2021792499","https://openalex.org/W2027823501","https://openalex.org/W2036193982","https://openalex.org/W2096782143","https://openalex.org/W2126499930","https://openalex.org/W2137578070","https://openalex.org/W2167191456","https://openalex.org/W2264465777","https://openalex.org/W2527905628","https://openalex.org/W2529904548","https://openalex.org/W2557867537","https://openalex.org/W2560322684","https://openalex.org/W2625652544","https://openalex.org/W2658569466","https://openalex.org/W2796582438","https://openalex.org/W2888059202","https://openalex.org/W2973740803","https://openalex.org/W2984280663","https://openalex.org/W2991564522"],"related_works":["https://openalex.org/W6958607482","https://openalex.org/W3167127179","https://openalex.org/W6920895877","https://openalex.org/W4206153642","https://openalex.org/W2900645032","https://openalex.org/W3085178505","https://openalex.org/W2908902360","https://openalex.org/W2964332468","https://openalex.org/W2625652544","https://openalex.org/W3046449570"],"abstract_inverted_index":{"AIMS:":[0],"To":[1],"describe":[2],"cost-effectiveness":[3,33,105,156],"of":[4,34,106,151,231,248,255,305],"pembrolizumab":[5,38,107,111,130,221,233,256,286],"plus":[6],"platinum":[7],"and":[8,53,61,92,161,170,182,209,216,282,307],"pemetrexed":[9],"chemotherapy":[10,40,45,109,132,143,235,258,288],"in":[11,16,195,223,271,293],"metastatic,":[12],"non-squamous,":[13],"NSCLC":[14,317],"patients":[15,116,165],"the":[17,32,59,70,126],"US.":[18],"MATERIALS":[19],"AND":[20,251],"METHODS:":[21],"A":[22],"model":[23],"is":[24,77,113,133,174,259],"developed":[25],"utilizing":[26],"partitioned":[27],"survival":[28,68],"analysis":[29],"to":[30,135,257,261,265],"estimate":[31],"KEYNOTE-189":[35],"trial":[36,60],"comparators":[37],"+":[39,42,108,131,234,287],"(carboplatin/cisplatin":[41],"pemetrexed)":[43],"vs":[44,110,142,145,179,184,191,242],"alone.":[46],"Clinical":[47],"efficacy,":[48],"treatment":[49,103,313],"utilization,":[50],"health":[51],"utility,":[52],"safety":[54],"data":[55],"are":[56,96,159,206],"derived":[57],"from":[58],"projected":[62,134,260],"over":[63],"20":[64],"years.":[65,153],"For":[66],"extrapolating":[67],"beyond":[69],"trial,":[71],"a":[72,188,266,298,310],"novel":[73],"SEER":[74],"population-data":[75],"approach":[76],"applied":[78],"(primary":[79],"analysis),":[80],"with":[81,117,166,187],"separate":[82],"estimation":[83],"via":[84],"traditional":[85],"parametric":[86],"extrapolation":[87],"methods.":[88],"Costs":[89],"for":[90,115,147,211,314],"drugs":[91],"non-drug":[93],"disease":[94],"management":[95],"also":[97],"incorporated.":[98],"Based":[99],"on":[100],"an":[101,148,246],"indirect":[102],"comparison,":[104],"monotherapy":[112,222],"evaluated":[114],"programmed":[118],"death-ligand":[119],"1":[120],"(PD-L1)":[121],"\u2265":[122,168,213,225],"50%.":[123],"RESULTS:":[124],"In":[125,164],"full":[127],"non-squamous":[128,275,316],"population,":[129],"increase":[136,194],"life":[137,152,172,203,237,263],"expectancy":[138,173,238,264],"by":[139,239,280],"2.04":[140],"years":[141],"(3.96":[144],"1.92),":[146],"approximate":[149],"doubling":[150],"Resultant":[154],"incremental":[155,201],"ratios":[157],"(ICERs)":[158],"$104,823/QALY":[160],"$87,242/life":[162],"year.":[163],"PD-L1":[167,196,212,224],"50%":[169,226],"1-49%,":[171,215],"more":[175],"than":[176],"doubled":[177],"(4.53":[178,241],"1.88":[180],"years)":[181,193,244],"(4.87":[183],"2.01":[185],"years),":[186],"32%":[189],"(2.60":[190],"1.97":[192],"<":[197],"1%":[198],"patients.":[199,318],"Corresponding":[200],"costs/quality-adjusted":[202],"year":[204],"(QALY)":[205],"$103,402,":[207],"$66,837,":[208],"$183,529":[210],"50%,":[214],"<1%":[217],"groups,":[218],"respectively.":[219],"Versus":[220],"patients,":[227],"representing":[228],"current":[229],"standard":[230],"care,":[232],"increases":[236],"65%":[240],"2.74":[243],"at":[245],"ICER":[247],"$147,365/QALY.":[249],"LIMITATIONS":[250],"CONCLUSIONS:":[252],"The":[253],"addition":[254],"extend":[262],"point":[267],"not":[268],"previously":[269,272],"seen":[270],"untreated":[273],"metastatic":[274,315],"NSCLC.":[276],"Although":[277],"ICERs":[278,290],"vary":[279],"sub-group":[281],"comparator,":[283],"results":[284],"suggest":[285],"yields":[289],"near,":[291],"or":[292],"most":[294],"cases,":[295],"well":[296],"below":[297],"3-times":[299],"US":[300],"per":[301],"capita":[302],"GDP":[303],"threshold":[304],"$180,000/QALY,":[306],"may":[308],"be":[309],"cost-effective":[311],"first-line":[312]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":14},{"year":2023,"cited_by_count":18},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":18},{"year":2020,"cited_by_count":24},{"year":2019,"cited_by_count":9}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2018-09-27T00:00:00"}